Boyd Thomas A 4
4 · PROGENICS PHARMACEUTICALS INC · Filed Oct 5, 2009
Insider Transaction Report
Form 4
Boyd Thomas A
Sr. VP, Product Dev.
Transactions
- Exercise/Conversion
ESPP (right to buy)
2009-10-01−2,666→ 0 totalExercise: $4.26From: 2009-10-01Exp: 2009-10-01→ Common Stock (2,666 underlying) - Exercise/Conversion
Common Stock
2009-10-01$4.26/sh+2,666$11,354→ 40,486 total - Award
ESPP (right to buy)
2009-10-01+2,266→ 2,266 totalExercise: $5.24From: 2010-04-01Exp: 2010-04-01→ Common Stock (2,266 underlying) - Tax Payment
Common Stock
2009-10-01$5.01/sh−2,426$12,154→ 38,060 total
Footnotes (5)
- [F1]Acquired upon the complete exercise of a grant under the Non-Qualified Employee Stock Purchase Plan, which grant was previously reported at the start of a six month option term, to acquire common stock up to an option amount which is 25% of the optionee's quarterly salary less $6,250, at a purchase price equal to the lower of 100% of the market value on the date of grant or 85% of the market value on the date of exercise.
- [F2]Includes shares of common stock acquired from the non-reportable exercise under a Qualified Employee Stock Purchase Plan.
- [F3]Granted under the Company's Non-Qualified Employeee Stock Purchase Plan.
- [F4]The option was granted on the first day of the option term and previously reported as a right to purchase shares of the Company's common stock at an exercise price equal to the market value on the date of grant. In accordance with the Non-Qualified Employee Stock Purchase Plan, the option is ultimately exercisable for an exercise price which is the lower of 100% of the market value on the grant date or 85% of the market value on the day prior to the exercise date. The number of shares exercised is based on the option amount divided by the lower of 100% of the market value on the grant date or 85% of the market value on the day prior to the exercise date.
- [F5]The option will be exercisable for that number of shares equal to the option amount (25% of the optionee's quarterly salary less $6,250) divided by the lesser of the market value of the common stock on the grant date or 85% of the market value on the day prior to the exercise date.